

Theravance Biopharma to Present at the Deutsche Bank 42nd Annual Health Care Conference

DUBLIN, April 27, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017 at 8:00 a.m. ET. The conference will be held from May 3 - 4 in Boston at the InterContinental Boston Hotel.



A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.

Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV[®] (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist ("LAMA") being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease ("COPD"). Our neprilysin ("NEP") inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase ("JAK") inhibitors for the treatment of a range of inflammatory intestinal diseases.

In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the "Closed Triple"), currently in development for the treatment of COPD and asthma.

For more information, please visit www.theravance.com.

THERAVANCE[®], the Cross/Star logo, and VIBATIV[®] are registered trademarks of the Theravance Biopharma group of companies.

Contact Information:

Alexander Dobbin
Head of Investor Relations
650-808-4045

investor.relations@theravance.com

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-300446771.html>

SOURCE Theravance Biopharma, Inc.

News Provided by Acquire Media